Workup for Asymptomatic Patient with WBC 21 and Platelets 1150
This patient requires urgent evaluation for a myeloproliferative neoplasm (MPN), specifically polycythemia vera (PV) or essential thrombocythemia (ET), with immediate testing for JAK2, CALR, and MPL mutations, followed by bone marrow biopsy if mutations are positive.
Initial Laboratory Confirmation
Start by repeating the complete blood count (CBC) with differential in a heparin or sodium citrate tube to exclude pseudothrombocytosis and confirm the elevated counts 1. Review the peripheral blood smear personally to assess:
- White cell morphology: Look for left shift (immature granulocytes), basophilia, eosinophilia, or dysplastic features that suggest MPN versus reactive process 2
- Platelet morphology: Assess for giant platelets or abnormal forms
- Red cell line: Check for polycythemia (elevated hemoglobin/hematocrit) which would point toward PV
Essential Diagnostic Tests
Order the following simultaneously:
- Complete metabolic panel with liver function tests
- C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) to assess for inflammatory/reactive causes 1
- Iron studies with ferritin - iron deficiency can mask PV and cause reactive thrombocytosis 1
- JAK2 V617F mutation testing - present in ~95% of PV and ~60% of ET cases 1
- If JAK2 negative: CALR and MPL mutation testing 1
Risk Stratification Context
Your patient's platelet count of 1150 × 10⁹/L exceeds the threshold (>1000 × 10⁹/L) that European LeukemiaNet guidelines identify as an indication for cytoreductive therapy 3. The WBC of 21 × 10⁹/L also exceeds the 15 × 10⁹/L threshold mentioned as an indication for treatment 3.
Bone Marrow Evaluation
If any mutation (JAK2, CALR, or MPL) is positive, proceed immediately to bone marrow aspiration and biopsy 1, 4. This is critical because:
- Confirms MPN diagnosis definitively
- Distinguishes between PV, ET, and other MPNs
- Rules out chronic myeloid leukemia (CML) - which can present with isolated thrombocytosis and requires BCR-ABL testing on bone marrow if peripheral blood is negative 4
- Assesses for myelofibrosis or progression
Important caveat: One case report demonstrated BCR-ABL positivity in bone marrow despite negative peripheral blood testing 4, so if clinical suspicion for CML is high (basophilia, marked left shift), test bone marrow even if peripheral blood BCR-ABL is negative.
Secondary Causes to Exclude
Before attributing findings to primary MPN, evaluate for:
- Infection/inflammation: Check CRP, review for recent illness, surgery, or trauma 5
- Iron deficiency: Can cause reactive thrombocytosis and mask underlying PV 3
- Malignancy: Solid tumors can cause reactive leukocytosis and thrombocytosis
- Recent splenectomy: Causes persistent elevation of both counts 6
- Medications: Corticosteroids, growth factors
Critical Pitfalls to Avoid
Do not dismiss as "reactive" without mutation testing - these counts are too high to observe without investigation 1
Do not rely solely on peripheral blood for BCR-ABL testing - bone marrow may be required 4
Do not delay workup because patient is asymptomatic - thrombosis risk is elevated even without symptoms, and the NCCN criteria for hydroxyurea resistance include platelet count >400 × 10⁹/L with WBC >10 × 10⁹/L as "uncontrolled myeloproliferation" 7
Check hematocrit carefully - if elevated (>45% in men, >42% in women), this points toward PV rather than ET and changes management significantly 3
Immediate Management Considerations
While awaiting test results:
- Assess cardiovascular risk factors aggressively - hypertension, diabetes, smoking 3
- Consider low-dose aspirin (81mg daily) if no contraindications, as this is recommended for all PV patients and high-risk ET patients 3
- Avoid dehydration - increases thrombosis risk
- Document any history of thrombosis - this immediately classifies patient as high-risk requiring cytoreduction 3, 7
Timeline for Cytoreductive Therapy
If MPN is confirmed, cytoreductive therapy with hydroxyurea is first-line at any age 3. Your patient's counts (platelets >1000 × 10⁹/L, WBC >15 × 10⁹/L) meet guideline thresholds for treatment initiation even in otherwise low-risk patients 3.